The effect of bevacizumab on human malignant melanoma cells with functional VEGF/ VEGFR2 autocrine and intracrine signaling loops

Neoplasia (United States)

Volumn 14, Issue 7, 2012, Pages 612-623

  Adamcic, Una ^a   Skowronski, Karolina ^a   Peters, Craig ^a   Morrison, Jodi ^a   Coomber, Brenda L ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL COMMUNICATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; MELANOMA; METASTASIS; MICROVASCULATURE; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84865647762     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.11948     Document Type: Article

References (62)

1. Ferrara N (2002). Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29, 10-14.
2. Ferrara N, Hillan KJ, and Novotny W (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333, 328-335.
3. Hurwitz H (2004). Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4, S62-S68.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
5. Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, et al. (2008). Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26, 4899-4905.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, and Davidson NE (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357, 2666-2676.
7. Jurado JM, Sanchez A, Pajares B, Perez E, Alonso L, and Alba E (2008). Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 10, 583-586.
8. Cohen MH, Gootenberg J, Keegan P, and Pazdur R (2007). FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12, 713-718.
9. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, and Rosenberg SA (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349, 427-434.
10. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE II, Marcello JE, Norfleet J, et al. (2009). Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer 101, 1986-1994.
11. McCarthy M (2003). Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361, 1959.
12. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, Wu H, Lesinski GB, Kendra K, Chen HX, et al. (2007). A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14, 2367-2376.
13. Hainsworth JD, Infante JR, Spigel DR, Peyton JD, Thompson DS, Lane CM, Clark BL, Rubin MS, Trent DF, and Burris HA III (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116, 4122-4129.
14. Grignol VP, Olencki T, Relekar K, Taylor C, Kibler A, Kefauver C, Wei L, Walker MJ, Chen HX, Kendra K, et al. (2011). A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma. J Immunother 34, 509-515.
15. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. (2003). In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9, 327-337.
16. Patyna S, Laird AD, Mendel DB, O'Farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, et al. (2006). SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther 5(7), 1774-1782.
17. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, et al. (2008). Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26(4), 650-656.
18. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, and Pryer NK (2003). Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with standard of care therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2(10), 1011-1021.
19. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, and Wilding G (2007). Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178(5), 1883-1887.
20. Neufeld G, Cohen T, Gengrinovitch S, and Poltorak Z (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13, 9-22.
21. Zachary I and Gliki G (2001). Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 49, 568-581.
22. Zeng H, Sanyal S, and Mukhopadhyay D (2001). Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276, 32714-32719.
23. Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, and Linderholm B (2008). An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol Cancer Res 6, 1630-1638.
24. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C, and Burian M (2001). Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111, 1834-1841.
25. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175, 1245-1252.
26. Zhang H, Li Y, Li H, Bassi R, Jimenez X, Witte L, Bohlen P, Hicklin D, and Zhu Z (2004). Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma 45, 1887-1897.
27. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ, and Fabra A (2004). Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signalling. J Invest Dermatol 123, 1151-1161.
28. Lacal PM, Ruffini F, Pagani E, and D'Atri S (2005). An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27, 1625-1632.
29. Lazar-Molnar E, Hegyesi H, Toth S, and Falus A (2000). Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12, 547-554.
30. Lee TH, Sen S, Sekine M, Hinton C, Fu Y, Avraham HK, and Avraham S (2007). Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 4, e186.
31. Samuel S, Fan F, Dang LH, Xia L, Gaur P, and Ellis LM (2011). Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30, 1205-1212.
32. Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, and Koprowsk H (1987). Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 40, 687-690.
33. Graham FL, Smiley J, Russell WC, and Nairn R (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36, 59-74.
34. Coomber BL (1995). Suramin inhibits C6 glioma-induced angiogenesis in vitro. J Cell Biochem 58, 199-207.
35. Bellamy WT, Richter L, Frutiger Y, and Grogan TM (1999). Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 59, 728-733.
36. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, and Brambilla E (1999). Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in nonsmall cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188, 369-377.
37. Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, et al. (2001). Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA 98, 10857-10862.
38. Graeven U, Fiedler W, Karpinski S, Ergün S, Kilic N, Rodeck U, Schmiegel W, and Hossfeld DK (1999). Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol 125, 621-629.
39. Sher I, Adham SA, Petrik J, and Coomber BL (2009). Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124, 553-561.
40. Gitay-Goren H, Halaban R, and Neufeld G (1993). Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 190, 702-708.
41. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, et al. (2000). Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536-540.
42. Seftor EA, Meltzer PS, Schatteman GC, Gruman LM, Hess AR, Kirschmann DA, Seftor RE, and Hendrix MJ (2002). Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 44, 17-27.
43. Folberg R, Hendrix MJ, and Maniotis AJ (2000). Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156, 361-381.
44. Folberg R and Maniotis AJ (2004). Vasculogenic mimicry. APMIS 112, 508-525.
45. Strizzi L, Hardy KM, Kirsammer GT, Gerami P, and Hendrix MJ (2011). Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest 91, 819-824.
46. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, Strizzi L, and Hendrix MJ (2010). Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70, 10340-10350.
47. Salven P, Heikkila P, and Joensuu H (1997). Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 76, 930-934.
48. Dougher M and Terman BI (1999). Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619-1627.
49. Wang Y, Fei D, Vanderlaan M, and Song A (2004). Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7, 335-345.
50. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, et al. (2006). Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24, 769-777.
51. Inoue S, Hartman A, Branch CD, Bucana CD, Bekele BN, Stephens LC, Chada S, and Ramesh R (2007). mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther 15, 287-294.
52. Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, Vasques L, and Soares R (2009). Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. J Cell Biochem 108, 1410-1417.
53. Lanahan AA, Hermans K, Claes F, Kerley-Hamilton JS, Zhuang ZW, Giordano FJ, Carmeliet P, and Simons M (2010). VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell 18, 713-724.
54. Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, and Fujimoto-Ouchi K (2010). Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 21, 687-694.
55. Takano S, Mashiko R, Osuka S, Ishikawa E, Ohneda O, and Matsumura A (2010). Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol 27, 89-94.
56. Li W and Keller G (2000). VEGF nuclear accumulation correlates with phenotypical changes in endothelial cells. J Cell Sci 113, 1525-1534.
57. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, and Dejana E (2006). Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol 174, 593-604.
58. Re RN and Cook JL (2006). An intracrine view of angiogenesis. Bioessays 28, 943-953.
59. Vaupel P, Kallinowski F, and Okunieff P (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49, 6449-6465.
60. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, and Claffey KP (1997). Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 108, 263-268.
61. Hicklin DJ and Ellis LM (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027.
62. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, and Ferrara N (2002). VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954-958.